Evidence map›Paper›PMID 29913161›Full record

ArticleJournal of molecular biology2018

The Solution Structure of CCL28 Reveals Structural Lability that Does Not Constrain Antifungal Activity.

Monica A Thomas, Jie He, Francis C Peterson, Anna R Huppler, Brian F Volkman

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Metamorphic Protein Folding Encodes Multiple Anti-Pathogens (Basel, Switzerland) · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Monica A ThomasDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Jie HeDepartment of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Francis C PetersonDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Anna R HupplerDepartment of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Brian F VolkmanDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: bvolkman@mcw.edu.
Medical College of Wisconsin · US

Funding

Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
Targeting CCL28 as therapy for obstructive lung diseaseR01AI120655 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2015 to 2018
$1.5M
Anti-Candida activity of CCL28 in oropharyngeal candidiasisK08DE026189 · NIDCR · MEDICAL COLLEGE OF WISCONSIN · PI HUPPLER, ANNA · 2017 to 2021
$860k
Validating CCL28 as a Target for Novel Asthma Therapies using NMR SpectroscopyF30HL134253 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI THOMAS, MONICA A · 2017 to 2019
$140k
NHLBI NIH HHS F30 HL134253NIAID NIH HHS R01 AI120655NIDCR NIH HHS K08 DE026189NIDCR NIH HHS L40 DE027274NIGMS NIH HHS T32 GM080202
6 · The paper itself

Abstract

The chemokine CCL28 is constitutively expressed in mucosal tissues and is abundant in low-salt mucosal secretions. Beyond its traditional role as a chemoattractant, CCL28 has been shown to act as a potent and broad-spectrum antimicrobial agent with particular efficacy against the commensal fungus and opportunistic pathogen Candida albicans. However, the structural features that allow CCL28 to perform its chemotactic and antimicrobial functions remain unknown. Here, we report the structure of CCL28, solved using nuclear magnetic resonance spectroscopy. CCL28 adopts the canonical chemokine tertiary fold, but also has a disordered C-terminal domain that is partially tethered to the core by a non-conserved disulfide bond. Structure-function analysis reveals that removal of the C-terminal tail reduces the antifungal activity of CCL28 without disrupting its structural integrity. Conversely, removal of the non-conserved disulfide bond destabilizes the tertiary fold of CCL28 without altering its antifungal effects. Moreover, we report that CCL28 unfolds in response to low pH but is stabilized by the presence of salt. To explore the physiologic relevance of the observed structural lability of CCL28, we investigated the effects of pH and salt on the antifungal activity of CCL28 in vitro. We found that low pH enhances the antifungal potency of CCL28, but also that this pH effect is independent of CCL28's tertiary fold. Given its dual role as a chemoattractant and antimicrobial agent, our results suggest that changes in the salt concentration or pH at mucosal sites may fine-tune CCL28's functional repertoire by adjusting the thermostability of its structure.

Indexed as

Models, MolecularProtein ConformationAnti-Infective AgentsCandida albicansChemokines, CCHumansHydrogen-Ion ConcentrationMagnetic Resonance SpectroscopyProtein StabilityProtein UnfoldingSaltsSolutionsStructure-Activity RelationshipThermodynamicsAnti-Infective AgentsCCL28 protein, humanChemokines, CCSaltsSolutionsCandidachemokineNMRpHsalt

Identifiers

PMID29913161
PMCPMC6103841
OpenAlexW2808393899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.